Skip to content
2000
Volume 4, Issue 1
  • ISSN: 1574-891X
  • E-ISSN: 2212-4071

Abstract

Doripenem (DPM) is the newest antimicrobial in the carbapenem class. It is a broad spectrum agent with activity against gram-positive, gram-negative and anaerobic bacteria. in vitro Susceptibility testing has demonstrated potent activity for many drug resistant gram-negative pathogens including some that are resistant to imipenem and meropenem. It appears to be less likely to induce resistance for certain pathogens compared to the other carbapenems. The purpose of this review is to introduce DPM and describe its potential role in managing infections due to multi-drug resistant gram-negative bacteria. This article also reviews recent patents related to the carbapenem class of antimicrobials.

Loading

Article metrics loading...

/content/journals/pri/10.2174/157489109787236283
2009-01-01
2025-09-07
Loading full text...

Full text loading...

/content/journals/pri/10.2174/157489109787236283
Loading

  • Article Type:
    Research Article
Keyword(s): carbapenem; Doripenem; multi-drug resistant; pharmacodynamics; pseudomonas
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test